# US 2004/0019919 A1 · Calcium binding proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019919 A1
- Document ID: US20040019919A1
- Status: Published application
- Kind: A1
- Application number: 10/380,705
- Filed: 2003-06-30
- Published: 2004-01-29
- Earliest claimed: 2000-09-14
- Inventors: Peter Sonderegger; Gustav Hintsch; Jochen Kinter; Virginija Meskenaite; Sabine Schrimpf; Lorenz Vogt; Andreas Zurlinden
- Web page: https://patentgrep.com/patent/US20040019919A1

## CPC

- C07K 14/4728: {Calcium binding proteins, e.g. calmodulin}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

There is described a novel class of calcium binding proteins of the nervous system, in particular calsyntenin-1-3. Calsyntenin proteins are valuable agents in the treatment of disorders of the nervous system, in particular the central nervous system. They are very useful for the development of drugs for the treatment of disorders of the nervous system.

## Claims

### Claim 1

An isolated polypeptide for the use as a pharmaceutical comprising an amino acid sequence at least 50% identical to a sequence selected from the group consisting of:
a) a full length amino acid sequence selected from the group consisting of Seq. Id. No. 2, Seq. Id. No. 4 and Seq. Id. No. 6,
b) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of: sequence of residues from about 46 to about 165, sequence of residues 166 to about 257, sequence of residues from about 774 to about 861 and sequence of residues from about 881 to about 981 of Seq. Id. No. 2,
c) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of: sequence of residues from about 66 to about 158, sequence of residues from about 182 to about 259, sequence of residues from about 751 to about 834 and sequence of residues from about 854 to about 955 of Seq. Id. No. 4,
d) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of: sequence of residues from about 51 to about 142, sequence of residues from about 167 to about 244, sequence of residues from about 759 to about 845 and sequence of residues from about 869 to about 956 of Seq Id. No. 6
e) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of: sequence of residues from about 881 to about 981 of Seq. Id. No. 2, sequence of residues from about 854 to about 955 of Seq. Id. No. 4 and sequence of residues from about 869 to about 956 of Seq Id. No. 6,
and having calcium binding activity and/or the capacity to bind to the Arp2/3 complex.

### Claim 2 (depends on 1)

The polypeptide of claim 1 wherein the polypeptide sequence is at least 60% identical and more preferably more than 65% identical to an amino acid sequence selected from the group consisting of:
a) a full length amino acid sequence selected from the group consisting of Seq. Id. No. 2, Seq. Id. No. 4 and Seq. Id. No. 6
b) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of: sequence of residues from about 46 to about 165, sequence of residues 166 to about 257, sequence of residues from about 774 to about 861 and sequence of residues from about 881 to about 981 of Seq. Id. No. 2,
c) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of: sequence of residues from about 66 to about 158, sequence of residues from about 182 to about 259, sequence of residues from about 751 to about 834 and sequence of residues from about 854 to about 955 of Seq. Id. No. 4,
d) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of: sequence of residues from about 51 to about 142, sequence of residues from about 167 to about 244, sequence of residues from about 759 to about 845 and sequence of residues from about 869 to about 956 of Seq Id. No. 6,
e) a polypeptide comprising at least one, preferably two, most preferably three of amino acid sequences selected from the group consisting of: sequence of residues from about 881 to about 981 of Seq. Id. No. 2, sequence of residues from about 854 to about 955 of Seq. Id. No. 4 and sequence of residues from about 869 to about 956 of Seq Id. No. 6,
and having calcium binding activity and/or the capacity to bind to the Arp2/3 complex.

### Claim 3

An isolated polypeptide for the use as a pharmaceutical comprising an amino acid sequence selected from
sequences comprising a stretch of at least 100 amino acids with a minimal identity percentage of 50%, preferably 55% and more preferably 60% to a amino acid sequence selected from the group consisting of Seq. Id. No. 2, Seq. Id. No. 4 and Seq. Id. No. 6, said sequences having calcium binding activity and/or the capacity to bind to the Arp2/3 complex.

### Claim 4

The polypeptide according to anyone of the preceding claims which
is a transmembrane protein and which
is expressed predominatly in cells of the nervous system.

### Claim 5 (depends on 4)

The polypeptide according to claim 4 which is expressed in neurons.

### Claim 6 (depends on 5)

The polypeptide according to claim 5 which is localised to the postsynaptic membrane of synapses.

### Claim 7 (depends on 6)

The polypeptide according to claim 6 which is localized in a membrane of a spine apparatus of spine synapses and in a membrane of subsynaptic endoplasmatic reticulum of shaft synapses.

### Claim 8 (depends on 4, 5, 6, 7)

The polypeptide according to anyone of claims 4 to 7 which is expressed in tumor cells.

### Claim 9

The polypeptide according to anyone of the preceding claims which has its major calcium-binding domain in the cytoplasmic compartment.

### Claim 10

The polypeptide according to anyone of the preceding claims which has at least one binding site for the Arp2/3 complex.

### Claim 11

An isolated nucleotide sequence encoding a polypeptide according to anyone of the preceding claims for the use as pharmaceutical.

### Claim 12

An isolated nucleotide sequence encoding a polypeptide as defined in anyone of the preceding claims which has, due to at least one point mutation, insertion or deletion, lost its function.

### Claim 13 (depends on 12)

The nucleotide sequence according to claim 12 for the use as a diagnostic tool.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising a polypeptide according to anyone of claims 1 to 10.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Pharmaceutical composition comprising a polypeptide as defined in anyone of claims 1 to 10 and/or a nucleotide sequence according to claim 11.

### Claim 16

Use of a polypeptide or a partial sequence thereof as defined in anyone of the preceding claims for the use as a tool for the development of a pharmaceutical.

### Claim 17

Use of a protein or a DNA sequence as defined in anyone of the preceding claims for the screening and for the preparation of a medicament for the treatment of disorders, in particular disorders of the nervous system, more particular of the central nervous system, most preferably the brain.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17)

Use according to claim 17, characterized in that said disorders, in particular of the nervous system, more particular of the brain, are disorders due to lack of cleavage or miscleavage or excessive cleavage of a protein as defined in one of claims 1-11 induced by at least one protease.

### Claim 19 (depends on 18)

Use according to claim 18, characterized in that the protease is tissue-type plasminogen activator, abbreviated as tPA, urokinase-type plasminogen activator, abbreviated as uPA, or plasmin or neurotrypsin, or thrombin, or neuropsin.

### Claim 20 (depends on 17, 18, 19)

Use according to anyone of claims 17 to 19, characterized in that said disorders, in particular of the nervous system, are due to perturbed processing of intracellular calcium signals.

### Claim 21 (depends on 17, 18, 19, 20)

Use according to claim anyone of claims 17 to 20, characterized in that said disorders, in particular of the nervous system, are due to perturbed processing of extracellular signals that regulate the cellular motility processes by means of regulating the activity of the Arp2/3 complex.

### Claim 22 (depends on 17, 18, 19, 20, 21)

Use according to one of claims 17 to 21, characterized in that the medicament is a medicament for the minimization of the tissue destruction during and/or

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

Use according to anyone of claims 17 to 22, characterized in that the medicament prevents the cell death of cells of the nervous system.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

Use of a DNA sequence or a protein as defined in anyone of claims 1-10 for the preparation of a medicament for the treatment of tumors, including prevention or reduction of the growth, the expansion, the infiltration and the metastasis of primary and metastatic tumors, in particular brain tumors or tumors of the retina.

### Claim 25 (depends on 24)

Use according to claim 24, characterized in that said tumors involve in their growth, expansion, infiltration, metastasis and promotion of blood vessels or neoangiogenesis an enhanced activity of the Arp2/3 complex.

### Claim 26 (depends on 25)

Use according to claim 25, characterized in that said enhanced activity of the Arp2/3 complex is mediated by an abnormal or excessive or reduced regulatory function of one of the sequences as defined in anyone of claima 1-10.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 24, 25, 26)

Use according to anyone of claims 24 to 26, characterized in hat said tumors involve in their growth, expansion, infiltration, metastasis and promotion of blood vessels or neoangiogenesis at least one protease functionally connected with a polypeptide as defined in anyone of the claims 1-10.

### Claim 28 (depends on 27)

Use according to claim 27, characterized in that the protease is a member of one of the following protease families:
Serine Protease family such as tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), plasmin, thrombin, neurotrypsin, neuropsin, elastases, cathepsin G,
Matrix Metalloproteinases family such as collagenases, gelatinases, stromelysins, matrylisins,
Cystein Proteases family such as cathepsin B and cathepsin D.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12)

A method for the production of polypeptides as defined in anyone of claims 1 to 10 or such polypeptide expressing cells, characterized in that suitable host cells are transfected with a DNA sequence as defined in claim 12 in a vector ensuring the expression of said DNA sequence in said host cell, and in that said transfected cells are cultured under suitable conditions allowing said expression.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A synthetic or chemical method for the production of polypeptides, peptides or nucleic acid sequences representing at least part of the sequences defined in claims 1 to 13 and having the ability to mimic or to block, respectively, the biological activity of calsyntenin, in particular the calcium binding activity.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

Use of the DNA sequences and/or the polypeptides as defined in anyone of claims 1 to 13 as tools in the screening of pharmaceutical drugs.

### Claim 32 (depends on 11)

Use of a sequence as defined in claim 11 as a means to produce antigens or as antigen for the production of antibodies.

### Claim 33 (depends on 12)

Transgenic non human animal, characterized in that it comprises an exogenous DNA sequence as defined in claim 12 in an environment allowing protein expression.

### Claim 34 (depends on 11, 12, 13)

Use of a DNA sequence as defined in claim 12 or 13 or fragments thereof for the preparation of a diagnostic preparation for the diagnosis of disorders due to defects in the genomic sequence comprising a DNA sequence according to claim 11.

### Claim 35 (depends on 12)

A vector or artificial chromosome comprising a DNA sequence as defined in claim 12 for the use in gene therapeutical applications in humans and in animals.

### Claim 36

An isolated polypeptide comprising an amino acid sequence which is at least 60% identical to the amino acid sequence of Seq.Id. No. 4.

### Claim 37 (depends on 36)

The polypeptide of claim 36 wherein the amino acid sequence is identical to Seq. Id. No. 4.

### Claim 38

An isolated polypeptide comprising an amino acid sequence which is at least 98.5% identical to the amino acid sequence of Seq. Id. No. 6.

### Claim at position 39 (depends on 37)

39 The polypeptide of claim 37 which is identical to Seq. Id. No. 6.

### Claim 40 (depends on 36, 37, 38, 39)

A nucleotide sequence encoding a polypeptide according to anyone of claims 36 to 39.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A protease which cleaves a polypeptide as defined in anyone of claims 1 to 10 in its extracellular part.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A cell extract comprising a protease which cleaves a polypeptide as defined in anyone of claims 1 to 10.
